[HTML] mdpi.com

[HTML][HTML] Human mesenchymal stem cell (hMSC) donor potency selection for the “first in cystic fibrosis” phase I clinical trial (CEASE-CF)

TL Bonfield, MT Sutton, DR Fletcher, J Reese-Koc… - Pharmaceuticals, 2023 - mdpi.com
Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to provide both
anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The clinical …
被引用次数：10 相关文章

Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF)

T Bonfield, M Sutton, D Fletcher… - Pharmaceuticals …, 2023 - europepmc.org
Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to provide both
anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The clinical …

Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF)

TL Bonfield, MT Sutton, DR Fletcher, J Reese-Koc… - 2023 - scholarworks.iupui.edu
Abstract Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to
provide both anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The …
[HTML] nih.gov

[HTML][HTML] Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF)

TL Bonfield, MT Sutton, DR Fletcher, J Reese-Koc… - …, 2023 - ncbi.nlm.nih.gov
Abstract Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to
provide both anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The …

Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the" First in Cystic Fibrosis" Phase I Clinical Trial (CEASE-CF).

TL Bonfield, MT Sutton, DR Fletcher… - Pharmaceuticals …, 2023 - search.ebscohost.com
Abstract Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to
provide both anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The …

Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF)

TL Bonfield, MT Sutton, DR Fletcher… - …, 2023 - search.proquest.com
Abstract Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to
provide both anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The …
[PDF] semanticscholar.org

[PDF][PDF] Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF)

TL Bonfield, MT Sutton, DR Fletcher… - …, 2023 - pdfs.semanticscholar.org
Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to provide both
anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The clinical …

Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the" First in Cystic Fibrosis" Phase I Clinical Trial (CEASE-CF)

TL Bonfield, MT Sutton, DR Fletcher… - Pharmaceuticals …, 2023 - pubmed.ncbi.nlm.nih.gov
Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to provide both
anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The clinical …
[PDF] iupui.edu

[PDF][PDF] Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the “First in Cystic Fibrosis” Phase I Clinical Trial (CEASE-CF)

TL Bonfield, MT Sutton, DR Fletcher… - …, 2023 - scholarworks.iupui.edu
Human Mesenchymal Stem Cell (hMSC) immunotherapy has been shown to provide both
anti-inflammatory and anti-microbial effectiveness in a variety of diseases. The clinical …